Cholecalciferol D3
Dietary Supplement2 tablets of 1200 IU daily from week 24 of gestation to 1 week after delivery
Other names: Vitamin D from Camette, Denmark
NCT Number: NCT00856947
The aim of this study is to prevent asthma symptoms (recurrent wheeze) in childhood by supplementation with high dose vitamin D to the mother during pregnancy. Participants are mothers and children of the ABC (Asthma Begins in Childhood) cohort. Mothers are recruited during pregnancy and receive daily supplement with 2400 IU of Vitamin D3 or placebo from week 24 og gestation to 1 week after delivery. In addition all mothers are advised to take the recommended dose of 400 IU vitamin D daily. The mothers in ABC also participate in an interventional trial with fish oil supplementation, and the vitamin D randomization is stratified by fish oil treatment group. The child is followed with acute and planned vits at the research unit, and wheeze is diagnosed according to predefined algorithms.
This study is active but is not currently recruiting participants.
Notify Me18 year and older
Female
Interventional
Phase 1
Copenhagen University Hospital of Copenhagen, Gentofte Municipality, Gentofte, Denmark
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Mother:
Exclusion criteria
Mother:
2 tablets of 1200 IU daily from week 24 of gestation to 1 week after delivery
Other names: Vitamin D from Camette, Denmark
2 tablets containing no active substance
Other names: Placebo tablets from Camette, Denmark
Time frame: 0 to 3 years of age
Age at onset of persistent wheeze diagnosed according to predefined algorithm of recurrent troublesome lung symptoms, response to treatment and relapse after withdrawal of treatment
Time frame: 0 to 3 years of age
Main analysis:
Secondary analyses:
Time frame: 6 and 18 months of age
Allergic sensitization at 6 and/or 18 months assessed by skin prick test and specific IgE in blood
Time frame: 0 to 3 years of age
Age at onset of eczema diagnosed prospectively by research doctors according to predefined algorithm based upon Hanifin and Rajka criteria
Time frame: 1 week after delivery
Time frame: 0 to 3 years of age
Time frame: 0 to 3 years of age
Age at onset of severe asthma exacerbation diagnosed by predefined criteria of acute severe asthma requiring oral/high dose inhaled steroids or acute hospital contact
Time frame: 0-3 years
Main analysis:
Secondary analyses:
Time frame: 0-3 years
Main analysis:
Secondary analysis
Time frame: 18 months
Main analysis Immune status at 18 months measured in stimulated whole blood as cytokine release (combined assessments by prinicipal component analyses)
Secondary analyses Composition of immune cell subsets in whole blood at birth and at 18 months of age
Time frame: 4 weeks and 2 years
Immune status measured in airway mucosal lining fluid at 4 weeks and 2 years of age (combined assessments by prinicipal component analyses for each age point)
Time frame: 6 months
In a secondary analyses, we will determine the effect of 17q21 genotype on the efficacy of vitamin D supplementation in the prevention of asthma/wheeze. We will compute hazard ratios for the reduction in asthma/wheeze risk associated with prenatal supplementation, stratified by rs12936231. rs12936231 is a functional SNP influencing expression of ORMDL3, and given the role of ORMDL3 as a key sphingolipid biosynthesis regulator, we will subsequently investigate the relative abundance of sphingolipids between those in the vitamin D Intervention arm and those in the placebo group, stratified by 17q21 genotype. Finally we will identify interactions between prenatal vitamin D supplementation, rs12936231 genotype and sphingolipid metabolism in the risk of asthma/wheeze by age three.
Time frame: 6 year
Caries and enamel defects (molar incisor hypomineralization, MIH) determined at a dental examination at age 6 years.
Time frame: 3-10 years of age
Asthma diagnosed from age 3 to 10 years based on the same predefined algorithm of recurrent troublesome lung symptoms, response to treatment after withdrawal of treatment, which was used for persistent wheeze at age 0-3 in phase 1 of the study. Primary outcome in phase 2 is current asthma at specific visits till age 10 years, which is diagnosed in children fulfilling the persistent wheeze algorithm at any point during the first 10 years of life and still needing inhaled corticosteroids at specific visits (3, 4, 5, 6, 8 and 10 years of age) to control the symptoms.
Time frame: 5-10 years of age
Spirometry measuring airflow assessed by FEV1, MMEF and FEV1/FVC ratio at age 5, 6, 8 and 10 years.
Time frame: 3-10 years of age
Prescribed medicine for infections. Types and length of infections
Time frame: 3- 10 years of age
Anthropometrics:
Clinical follow up on the development of weight in kg (calibrated digital weight scales), height in cm (Harpenden stadiometer), waist-, thorax- and head circumference in cm (using tape; 3 times each) at every visit till age 10 years assessed longitudinally in the research clinic.
Time frame: 3-10 years of age
Age at onset of eczema diagnosed prospectively by research doctors according to predefined algorithm based upon Hanifin and Rajka criteria
Time frame: 6-10 years of age
Allergic sensitization at 6 and 10 years of age assessed by skin prick test (ALK-Abelló, Denmark) and specific IgE in blood (ImmunoCAP, PHarmacia Diagnostics AB, Sweden).
Time frame: 3-10 years of age
Immune status measured in airway mucosal lining fluid at 3, 6 and 10 years of age (combined assessments by principal component analyses for each age point).
Time frame: 3-10 years of age
Allergic rhinitis will be diagnosed by combining allergic sensitization with symptom recording of troublesome congestion or sneezing or runny nose upon relevant exposure to allergens at age 3, 4, 5, 6, 8 and 10 years.
Time frame: 3-10 years of age
Age at onset and number of severe asthma exacerbation diagnosed by predefined criteria of acute severe asthma requiring oral/ high dose inhaled steroids or acute hospital contact
Time frame: 3-10 years of age
Measured by plethysmography (sRaw) at age 3, 4, 5, 6, 8 and 10 years.
Time frame: 3-5 years of age
Multiple breath wash-out using SF6 and N2 as inert gasses to determined LCI, Scond and Sacin at ages 3, 4 and 5 years.
Time frame: at 6 years of age
Provocative dose of methacholine leading to a 20% drop in FEV1 from baseline (PD20 value) at age 6 years.
Time frame: 3-13 years of age
Body composition measured as fat mass, lean mass, bone mineral content (BMC) and bone mineral density assessed (BMD) through DXA scans at 3, 6 and 13 years of age.
Body impedance measurements at 10 years of age.
Time frame: 6-10 years of age
Measurement of fractional exhaled nitric oxide (FeNO) at age 6, 8 and 10 years
Time frame: 10 years of age
A 2,5 hours cognitive evaluation at 10 years of age. Cognitive functions from a broad spectrum of cognitive domains will be assessed with subtests both using paper pencil tests and Cambridge Neuropsychological Test Automated Battery .
Time frame: 10 years of age
MRI scanning of the Brain
Time frame: 6- 10 years of age
Questionnaires will be administered to the parents.
Time frame: 10 years of age
Behavioral and psychopathological dimensions will be assessed at 10 years of age.
The childrens' potential psychiatric diagnoses will be ascertained through the semi-structured clinical interview Schedule for Affective Disorders and Schizophrenia for School-Age Children - Present and Lifetime Version (K-SADS-PL) first with a parent and next with the child.
Time frame: 6, 8 and 10 years of age
The Strengths and Difficulties Questionnaire (SDQ) is a brief behavioural screening questionnaire about 3-16 year olds. Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology and behavior problems. Scores will be calculated form the questionnaires in order validated methods
Time frame: 8 and 10 years of age
The ADHD Rating Scale obtains parent ratings regarding the frequency of each ADHD symptom based on DSM criteria.
Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology and behavior problems. Scores will be calculated form the questionnaires. Scores will be calculated form the questionnaires in order validated methods.
Time frame: 10 years of age
The SRS-2 identifies social impairment associated with autism spectrum disorders (ASDs) and quantifies its severity Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology. Scores will be calculated form the questionnaires. Scores will be calculated form the questionnaires in order validated methods.
Time frame: 10 years of age
The Child Behavior Checklist (CBCL) is a widely used questionnaire to assess behavioral and emotional problems.
Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology and behavior problems. Scores will be calculated form the questionnaires. Scores will be calculated form the questionnaires in order validated methods.
Time frame: 10 years of age
The BRIEF-2 is a set of questionnaires for parents and teachers , designed to evaluate executive function from multiple perspectives.
Questionnaires will be administered to the parents to obtain their evaluation of their child's potential psychopathology. Scores will be calculated form the questionnaires. Scores will be calculated form the questionnaires in order validated methods.
Time frame: 0-13 years of age
Description: Assessed by medical record checks including all radiologically verified fractures of larger long bones (i.e. clavicle, radius, ulna, tibia, fibula, femur and humerus). Outcome analyses: total no. of fractures age 0-13 years.
Copenhagen Studies on Asthma in Childhood
Other
Vitamin D Supplementation During Pregnancy for Prevention of Asthma in Childhood: An Interventional Trial in the ABC (Asthma Begins in Childhood) Cohort
Acronym: ABCvitaminD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06570889
Allergy, Asthma
Gentofte Municipality, Denmark
View Trial DetailsNCT06560255
Allergy, Asthma
Gentofte Municipality, Denmark
View Trial DetailsNCT00438646
Asthma, Bronchial Diseases
Chapel Hill, North Carolina, United States
View Trial DetailsNCT00798226
Allergy, Asthma
Gentofte Municipality, Gentofte, Denmark
View Trial Details